Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers

Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers

Background: Coronavirus disease (COVID-19) is a mild to severe infectious respiratory illness caused by the SARS-CoV-2 virus. Based on the numerous pieces of evidence regarding the role of opioids in immune function, viral replication, and virus-mediated pathology, we decided to assess the incidence...

Full description

Bibliographic Details
Main Authors:	Samira Khani, Javad Tafaroji, Mehdi Yaghoubi, Mohammad Javad Emami Kazemabad, Seyed Amir Hejazi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Pharmacology
Subjects:	COVID-19 opioid immunodulation opioid agonist methadone maintenance program
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1105176/full

Similar Items

Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran
by: Alireza Noroozi, et al.
Published: (2023-05-01)

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
by: Ashish P. Thakrar, et al.
Published: (2023-02-01)

Interim opioid agonist treatment for opioid addiction: a systematic review
by: Laura Samsó Jofra, et al.
Published: (2022-01-01)

Large variations in all-cause and overdose mortality among >13,000 patients in and out of opioid maintenance treatment in different settings: a comparative registry linkage study
by: Roman Gabrhelík, et al.
Published: (2023-09-01)

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system
by: Guido Mannaioni, et al.
Published: (2023-01-01)

The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting
by: Lindsay Mackay, et al.
Published: (2021-04-01)

Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system
by: Guido Mannaioni, et al.
Published: (2023-12-01)

Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa
by: Andrew Scheibe, et al.
Published: (2020-02-01)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
by: Michael Soyka
Published: (2021-11-01)

The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review
by: Madeline C. Frost, et al.
Published: (2021-10-01)

Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service
by: Courtney D. Nordeck, et al.
Published: (2022-03-01)

Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
by: Anne Berit Bech, et al.
Published: (2019-07-01)

Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
by: Michael Curtis, et al.
Published: (2023-03-01)

Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study
by: Jacques Besson, et al.
Published: (2014-03-01)

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study
by: Narjes Shojaati, et al.
Published: (2023-08-01)

A Preliminary Study of Sexual Dysfunction in Male Opioid-Dependants under Methadone Maintenance Treatment
by: Masoudeh Babakhanian, et al.
Published: (2011-08-01)

High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
by: Samy J. Galvez, et al.
Published: (2023-11-01)

Corrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
by: Samy J. Galvez, et al.
Published: (2024-01-01)

Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment
by: Jens Reimer, et al.
Published: (2019-12-01)

Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
by: Li-Tzy Wu, et al.
Published: (2023-09-01)

Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
by: Li-Tzy Wu, et al.
Published: (2023-08-01)

Perceived barriers to methadone maintenance treatment among Iranian opioid users
by: Maryam Khazaee-Pool, et al.
Published: (2018-06-01)

Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting
by: Laura Beamish, et al.
Published: (2019-09-01)

Biphalin—A Potent Opioid Agonist—As a Panacea for Opioid System-Dependent Pathophysiological Diseases?
by: Patrycja Redkiewicz, et al.
Published: (2021-10-01)

The four-factor personality model and its qualitative correlates among opioid agonist therapy clients
by: Ioan T. Mahu, et al.
Published: (2023-06-01)

Acupuncture for Opioid Dependence Patients Receiving Methadone Maintenance Treatment: A Network Meta-Analysis
by: Hao Wen, et al.
Published: (2021-12-01)

Opioid Substitution: More than Only Methadone!
by: M. Torrens
Published: (2022-06-01)

Improving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals’ attitudes and clinical practice
by: Sarah Webster, et al.
Published: (2018-01-01)

Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences
by: Rebecca McDonald, et al.
Published: (2023-09-01)

Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review
by: Lara L. Nixon, et al.
Published: (2019-07-01)

Opioid Use Disorder Induces Oxidative Stress and Inflammation: The Attenuating Effect of Methadone Maintenance Treatment
by: Ali Salarian, et al.
Published: (2018-02-01)

Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway
by: Marte Handal, et al.
Published: (2019-10-01)

Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland
by: Marie Claire Van Hout, et al.
Published: (2018-06-01)

Stigmatization as a barrier in opioid substitution therapy patients
by: M.J. Gonçalves, et al.
Published: (2021-04-01)

<it>In vivo </it>antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
by: Guillemyn Karel, et al.
Published: (2012-01-01)

Methadone Maintenance Therapy (MMT) and Alternatives in Opioid Use Disorder: Reviewing the latest advancements, outcomes, and challenges in substitutional therapy for opioid addiction - literature review
by: Karolina Koszyczarek, et al.
Published: (2024-02-01)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
by: Dobischok S, et al.
Published: (2022-12-01)

Methadone for Opioid Use Treatment during Pregnancy: Trends in Postpartum Dose Adjustments
by: Clara Ward, et al.
Published: (2020-07-01)

Opioid-Induced Hyperalgesia (OIH): Case Study of a Woman with Metastatic Colon Cancer
by: Naeemeh Dini, et al.
Published: (2023-09-01)

Unspecified opioids among opioid overdoses in Oslo, Norway
by: Zahra Zeineb Iqbal, et al.
Published: (2022-04-01)